The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1) cleavage. Interestingly, gliptins can also improve strok...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiazza, Fausto, Tammen, Harald, Pintana, Hiranya, Lietzau, Grazyna, Collino, Massimo, Nyström, Thomas, Klein, Thomas, Darsalia, Vladimer, Patrone, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960142/
https://www.ncbi.nlm.nih.gov/pubmed/29776406
http://dx.doi.org/10.1186/s12933-018-0702-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960142/
https://www.ncbi.nlm.nih.gov/pubmed/29776406
http://dx.doi.org/10.1186/s12933-018-0702-3

Ejemplares similares